US Patent

US11382922 — Aqueous oral pharmaceutical suspension compositions

Composition of Matter · Assigned to Reveragen Biopharma Inc · Expires 2040-07-16 · 14y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an aqueous oral pharmaceutical suspension composition containing vamorolone Form I and methods for its preparation and use.

USPTO Abstract

Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Drugs covered by this patent

Patent Metadata

Patent number
US11382922
Jurisdiction
US
Classification
Composition of Matter
Expires
2040-07-16
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Reveragen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.